A5024051589- Diabetes Treatment and Management
- Obesity and Health Practices
- Metabolism, Diabetes, and Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Research
- Bariatric Surgery and Outcomes
- Pancreatic function and diabetes
- Peptidase Inhibition and Analysis
- Diet and metabolism studies
- Obesity, Physical Activity, Diet
- Chronic Disease Management Strategies
- Muscle Physiology and Disorders
- Lipoproteins and Cardiovascular Health
- Healthcare cost, quality, practices
- Medication Adherence and Compliance
- Adipose Tissue and Metabolism
- Nutrition and Health in Aging
- Diabetes and associated disorders
- Pharmaceutical Practices and Patient Outcomes
- Neuropeptides and Animal Physiology
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Eating Disorders and Behaviors
- Gastrointestinal Bleeding Diagnosis and Treatment
- Pharmaceutical studies and practices
Novo Nordisk (Switzerland)
2018-2021
University of Copenhagen
2011-2017
Gentofte Hospital
2011-2017
Novo Nordisk (Denmark)
2015-2016
Abstract Background There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective the CAPTURE study was to estimate established CVD and its management adults T2D across 13 countries from five continents. Additional objectives were further characterize sample regarding demographics, clinical parameters medication usage, particular reference blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists...
Abstract Aims Despite increased recognition as a chronic disease, obesity remains greatly underdiagnosed and undertreated. We aimed to identify international perceptions, attitudes, behaviours barriers effective care in people with (PwO) healthcare professionals (HCPs). Materials methods An online survey was conducted 11 countries. Participants were adults HCPs who primarily concerned direct patient care. Results A total of 14 502 PwO 2785 completed the survey. Most (68%) (88%) agreed that...
Background. Hypoglycemia and fear of hypoglycemia threaten individuals' ability to work drive. We studied the effect on individual society, with a focus possible implications new European union legislation patients' continued Methods. A cross-sectional survey Danish Diabetes Association members was conducted investigate societal consequences hypoglycemia. Results. total 3117/9951 individuals type 1 diabetes (T1DM) (32.2%) or 2 (T2DM) (67.8%) completed survey. The calculated incidence rates...
People with obesity (PwO) often struggle to achieve and maintain weight loss. This can perpetuate and/or be influenced by feelings of low motivation. analysis from ACTION-IO data identified factors associated PwO motivation lose weight.PwO completed an online survey in 11 countries. Exploratory multinomial logistic regression analyses independent variables self-report feeling motivated versus not weight.Data 10,854 were included (5,369 motivated; 3,312 neutral; 2,173 motivated). Variables...
Inhibition of dipeptidyl peptidase 4 (DPP4) is thought to intensify the physiological effects incretin hormones. We investigated DPP4 inhibition on plasma levels glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP1), effect, glucose tolerance, gastrointestinal-mediated disposal (GIGD) and gastric emptying in healthy subjects.A randomised, controlled open-labelled study.Ten subjects (six women; age, 40±5 years (mean±s.e.m.); BMI, 24±3 kg/m(2); fasting glucose,...
Objective. The aim of this explorative study was to evaluate double-balloon enteroscopy (DBE) as a new tool for collecting mucosal biopsies from well-defined parts the entire small and large bowel in patients with type 2 diabetes matched healthy subjects. Material methods. Twelve subjects 12 body mass index age-matched underwent anterograde retrograde DBE under nurse-administered propofol sedation on two separate days. We attempted collect every 30 cm pylorus rectum. Results. A mean 21...
In both randomized controlled trials and real-world studies, liraglutide has demonstrated glycemic body weight benefits in patients with type 2 diabetes. However, persistence diabetes medication can be challenging. This study compared glycated hemoglobin (HbA1c) other outcomes who continued treatment for over 12 months those discontinued earlier, a real-life setting. is retrospective of adult from Maccabi Healthcare Services Israel, initiated 2010 to 2015. Mean HbA1c change initiation after...
Objectives: Obesity is a growing issue with increasing impact on healthcare budgets, yet very little known about weight loss experiences of people body mass index (BMI)≥30kg/m2 and their willingness to try pay for interventions (WLI). The objective this survey was gather knowledge among obese severely people.Methods: 1,003 Danish >18 years age BMI≥30 who wanted lose completed an online survey. Data included demographics, experience WLI, awareness anti-obesity medication (AOM), WLI including...
Liraglutide has demonstrated a significant reduction in the primary major composite cardiovascular (CV) outcome (CV death, non-fatal myocardial infarction, stroke). This study aimed to determine cost–utility of adding liraglutide standard care (SoC) for treating type 2 diabetes (T2D) Thailand three cohorts: people with atherosclerotic disease (ASCVD), no ASCVD, and all T2D. A Markov model was developed capture long-term costs outcomes under perspective healthcare system. Costs were based on...
Our objective was to investigate willingness pay (WTP) for biphasic insulin aspart 30/70 (BIAsp 30) in patients with type 2 diabetes mellitus (T2DM) India. A multicenter, prospective, non-interventional, preference study conducted that assessed WTP BIAsp 30 an pen (FlexPen® or Penfill® device) India T2DM previously treated human (BHI) vials and believed be able treatment. The primary endpoint the proportion of willing continue after 12 weeks' Secondary endpoints included change from baseline...
Objective: In both randomized, controlled trials and real-world studies, liraglutide (Victoza®) has demonstrated glycemic body weight benefits in patients with type 2 diabetes mellitus (T2DM). To achieve long-term beneficial outcomes, persistence treatment is important; however, this can be challenging injectable drugs. study, we examined the association of adherence to metabolic changes. Methods: A retrospective analysis T2DM (≥18 years old) from Maccabi Healthcare Services, Israel, who...
Background and aim: The association between LDL levels, CVD the benefits of statin use are well established. CAPTURE study estimated contemporary (2019) global prevalence medication in adults with type 2 diabetes across 13 countries. This post hoc analysis assessed serum lipid status people without (NoCVD), established CVD, atherosclerotic (AsCVD, a subgroup CVD). Methods: was multinational, cross-sectional non-interventional study. Participant information on status, profiles, were...